Skip to main content
Premium Trial:

Request an Annual Quote

Elucida Oncology Begins Trial of Targeted Therapy in Folate Receptor-Alpha Overexpressing Cancers

NEW YORK – Monmouth Junction, New Jersey-based Elucida Oncology said on Friday it has dosed the first patient in a Phase I/II trial of its C'Dot drug conjugate ELU001 for advanced cancers overexpressing folate receptor-alpha.

ELU001 is a next-generation antibody drug conjugate designed to target and penetrate cancer cells that overexpress folate receptor-alpha and deliver a higher therapeutic payload to tumors. Based on prior research, Elucida expects the drug to have broad activity across solid tumor types, particularly ovarian cancers, which commonly display folate receptor-alpha overexpression.

The company submitted an investigational new drug application with the US Food and Drug administration in July for ELU001, which allowed it to launch this Phase I/II trial in folate receptor-positive solid tumors.

The basket trial has two parts: a dose-escalation portion to determine the maximum tolerated and Phase II dose of ELU001 and another portion to study the activity of the drug within different cohorts of patients. The company expects to enroll patients with ovarian, endometrial, colorectal, gastric, gastroesophageal junction, triple-negative breast, non-small cell lung, and bile duct cancers. The tumor types that respond well to ELU001 in the first portion of the study will graduate to the second portion for further evaluation.